{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:30:37Z","timestamp":1786995037558,"version":"build-2736575974"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","nmd-journal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.nmd.2025.105313","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T12:01:07Z","timestamp":1739793667000},"page":"105313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Mortality of symptomatic children with spinal muscular atrophy in the era of disease-modifying therapies"],"prefix":"10.1016","volume":"49","author":[{"given":"R","family":"Finnegan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AM","family":"Rohwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Scoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Main","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Baranello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Manzur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Munot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.nmd.2025.105313_bib0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","article-title":"Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study","volume":"6","author":"Wei\u00df","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.nmd.2025.105313_bib0002","unstructured":"National Institute for Health and Care Excellence: risdiplam for treating spinal muscular atrophy. December 2023. Risdiplam for treating spinal muscular atrophy (nice.org.uk)."},{"key":"10.1016\/j.nmd.2025.105313_bib0003","unstructured":"National Institute for Health and Care Excellence: nusinersen for treating spinal muscular atrophy. July 2019. Nusinersen for treating spinal muscular atrophy (nice.org.uk)."},{"key":"10.1016\/j.nmd.2025.105313_bib0004","series-title":"1 Recommendations | onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy | guidance |","year":"2023"},{"issue":"9","key":"10.1016\/j.nmd.2025.105313_bib0005","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/14712598.2022.2066471","article-title":"Onasemnogene abeparvovec for the treatment of spinal muscular atrophy","volume":"22","author":"McMillan","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.nmd.2025.105313_bib0006","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.nmd.2025.105313_bib0007","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s40120-023-00489-2","article-title":"Cost-effectiveness of newborn screening for spinal muscular atrophy in England","volume":"12","author":"Weidlich","year":"2023","journal-title":"Neurol Ther"},{"key":"10.1016\/j.nmd.2025.105313_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2024.1366943","article-title":"Respiratory morbidity in patients with spinal muscular atrophy \u2013 a changing world in the light of disease-modifying therapies","author":"Lagae","year":"2024","journal-title":"Front Pediatr"},{"issue":"1","key":"10.1016\/j.nmd.2025.105313_bib0009","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1164\/rccm.202111-2577LE","article-title":"Can breathing pattern assessment predict the need of ventilatory support in treated infants with spinal muscular atrophy type 1?","volume":"206","author":"LoMauro","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.nmd.2025.105313_bib0010","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.tins.2020.11.009","article-title":"Spinal muscular atrophy: in the challenge lies a solution","volume":"44","author":"Wirth","year":"2021","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.nmd.2025.105313_bib0011","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejpn.2024.06.004","article-title":"An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies","volume":"51","author":"Giess","year":"2024","journal-title":"Eur J Paediatr Neurol"},{"issue":"6","key":"10.1016\/j.nmd.2025.105313_bib0012","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/jamapediatrics.2024.0489","article-title":"Universal newborn screening for spinal muscular atrophy","volume":"178","author":"Oskoui","year":"2024","journal-title":"JAMA Pediatr"},{"issue":"9","key":"10.1016\/j.nmd.2025.105313_bib0013","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.nmd.2025.105313_bib0014","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"et al. for the SMA Care group. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscular Disord"},{"key":"10.1016\/j.nmd.2025.105313_bib0015","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200310","article-title":"Spinal muscular atrophy update in best practices","author":"Schroth","year":"2024","journal-title":"Neurol Clin Pract"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896625000409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896625000409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:16:37Z","timestamp":1746749797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896625000409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":15,"alternative-id":["S0960896625000409"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2025.105313","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mortality of symptomatic children with spinal muscular atrophy in the era of disease-modifying therapies","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2025.105313","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105313"}}